Migraine Trial, Recruiting (NCT05570149)

Migraine Trial, Recruiting NCT05570149 Sponsor: IRCCS San Raffaele Roma Condition: Migraine

Printed from Voxsanity (voxsanity.com.au) — NCT05570149 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Migraine

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged between 18 and 75 years old
Both men and women are eligible
People who are willing to sign a consent form agreeing to take part in the trial
People who have had at least 8 days per month of severe, disabling migraine for the past 3 months (known as high frequency episodic migraine)
People who have been diagnosed with chronic migraine according to recognised international diagnostic guidelines

Who may not be able to join:

People whose headaches are caused by something other than migraine
People who are known to have had a bad reaction or intolerance to the study drug (eptinezumab) or any of its ingredients
People who are currently being treated with another medication in the same class of drugs (monoclonal antibodies) (confirm with trial site)
People who have a vascular (blood vessel) disease or a condition called Raynaud's (a condition affecting blood flow, usually to the fingers and toes)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Piero Barbanti, MD, PhD, IRCCS San Raffaele Roma

Phone: +393357071457

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05570149

Sponsor: IRCCS San Raffaele Roma

Phase: Not Applicable

Status: Recruiting

Condition: Migraine

Trial contact: +393357071457

More information: https://clinicaltrials.gov/study/NCT05570149

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged between 18 and 75 years old
Both men and women are eligible
People who are willing to sign a consent form agreeing to take part in the trial
People who have had at least 8 days per month of severe, disabling migraine for the past 3 months (known as high frequency episodic migraine)
People who have been diagnosed with chronic migraine according to recognised international diagnostic guidelines

Who may not be able to join:

People whose headaches are caused by something other than migraine
People who are known to have had a bad reaction or intolerance to the study drug (eptinezumab) or any of its ingredients
People who are currently being treated with another medication in the same class of drugs (monoclonal antibodies) (confirm with trial site)
People who have a vascular (blood vessel) disease or a condition called Raynaud's (a condition affecting blood flow, usually to the fingers and toes)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS San Raffaele Roma

Registry

ClinicalTrials.gov

Start date

1 January 2023

Est. completion

31 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Change from baseline in monthly migraine days (MMD) in HFEM or monthly headache days (MHD) in CM;; Change from baseline in MMD in HFEM or MHD in CM;; Change from baseline in MMD in HFEM or MHD in CM;; Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov